DSIP

An amphiphilic synthetic nonapeptide with no identified gene precursor or cloned receptor.

Molecular Profile

Type
Synthetic peptide (nonapeptide)
Molecular formula
C35H48N10O15
Molecular weight
848.8 g/mol
CAS number
62568-57-4
Amino acids
9
Sequence
WAGGDASGE
Modification
None (native peptide)

Mechanism & Target Class

An amphiphilic nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, ~850 Da) whose gene precursor has not been identified and for which no dedicated receptor has been cloned. It has no close sequence homologues and co-localizes immunohistochemically with other small peptides in structural distribution-mapping studies. The unmodified backbone is subject to rapid degradation by aminopeptidases, giving a short in-vitro half-life that is relevant to handling and assay design; alpha-Asp/beta-Asp isomerization at the Asp residues is a recognized identity consideration.

Storage & Handling

Lyophilized
-20 °C; protect from light and moisture; stable up to 1 year.
Handling
Sensitive to aminopeptidase cleavage; alpha-Asp/beta-Asp isomerization is relevant to identity; protect from light.

Primary Database

PubChem CID 68816 ↗

References (22)

  1. Reviews

    1

    Gimble JM, et al. (2009). Obes. Rev.

    DOI: 10.1111/j.1467-789X.2009.00661.x

  2. 2

    Kovalzon VM, Strekalova TV (2006). J. Neurochem.

    DOI: 10.1111/j.1471-4159.2006.03693.x

  3. 3

    Graf MV, Kastin AJ (1986). Peptides

    DOI: 10.1016/0196-9781(86)90148-8PubMed 3550726

  4. Clinical

    4

    Westrin A, Ekman R, Träskman-Bendz L (1998). Biol. Psychiatry

    DOI: 10.1016/S0006-3223(97)00254-0PubMed 9606527

  5. 5

    Bes F, Hofman W, Schuur J, van Boxtel C (1992). Neuropsychobiology

    DOI: 10.1159/000118919PubMed 1299794

  6. 6

    Schneider-Helmert D (1986). Eur. Neurol.

    DOI: 10.1159/000116050PubMed 3792404

  7. 7

    Schneider-Helmert D, Schoenenberger GA (1981). Experientia

    DOI: 10.1007/BF01971753PubMed 7028502

  8. 8

    Dick P, Grandjean ME, Tissot R (1983). Neuropsychobiology

    DOI: 10.1159/000118012PubMed 6328354

  9. 9

    Dick P, et al. (1984). Eur. Neurol.

    DOI: 10.1159/000115715PubMed 6548969

  10. 10

    Lindström LH, Ekman R, Walleus H, Widerlöv E (1985). Prog. Neuropsychopharmacol. Biol. Psychiatry

    DOI: 10.1016/0278-5846(85)90182-4PubMed 2859636

  11. 11

    Ernst A, et al. (1987). J. Neurol.

    DOI: 10.1007/BF00314191PubMed 2448424

  12. Primary research

    12

    Sudakova KV, et al. (2004). Pathophysiology

    DOI: 10.1016/j.pathophys.2004.03.003PubMed 15364118

  13. 13

    Charnay Y, et al. (1989). Neuroendocrinology

    DOI: 10.1159/000125110PubMed 2657475

  14. 14

    Iyer KS, et al. (1988). Proc. Natl. Acad. Sci. USA

    DOI: 10.1073/pnas.85.10.3653

  15. 15

    Graf MV, Schoenenberger GA (1987). J. Neurochem.

    DOI: 10.1111/j.1471-4159.1987.tb05654.xPubMed 3029331

  16. 16

    Graf MV, Kastin AJ, Coy DH, Fischman AJ (1985). Neuroendocrinology

    DOI: 10.1159/000124200PubMed 2995861

  17. 17

    Graf MV, et al. (1984). J. Clin. Endocrinol. Metab.

    DOI: 10.1210/jcem-59-1-127PubMed 6547144

  18. 18

    Monnier M, et al. (1977). Experientia

    DOI: 10.1007/BF01922266

  19. 19

    Schoenenberger GA, Monnier M (1977). Proc Natl Acad Sci USA

    DOI: 10.1073/pnas.74.3.1282

  20. 20

    Marks N, Stern F, Kastin AJ, Coy DH (1977). Brain Res Bull

    DOI: 10.1016/0361-9230(77)90058-2PubMed 606344

  21. 21

    Khvatova EM, Rubanova NA, Prudchenko IA, Mikhaleva II (1995). FEBS Lett.

    DOI: 10.1016/0014-5793(95)00661-rPubMed 7628639

  22. 22

    Shustanova TA, et al. (2001). Biochemistry (Mosc)

    DOI: 10.1023/A:1010255230338PubMed 11421812